Preferred Label : Liraglutide;
MeSH definition : An analog of GLUCAGON-LIKE PEPTIDE 1 and agonist of the GLUCAGON-LIKE PEPTIDE 1 RECEPTOR
that is used as a HYPOGLYCEMIC AGENT and supplemental therapy in the treatment of
DIABETES MELLITUS by patients who do not respond to METFORMIN.;
MeSH hyponym : victoza; NN 2211; Saxenda; 2211, NN; NN2211; NN-2211;
MeSH Related Number : 204656-20-2;
Is substance : O;
UNII : 839I73S42A;
InChIKey : YSDQQAXHVYUZIW-QCIJIYAXSA-N;
Origin ID : D000069450;
UMLS CUI : C1456408;
ATC code(s)
Allowable qualifiers
CISMeF manual mappings
Pharmacological action(s)
Record concept(s)
Related MeSH Supplementary Concept(s)
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
An analog of GLUCAGON-LIKE PEPTIDE 1 and agonist of the GLUCAGON-LIKE PEPTIDE 1 RECEPTOR
that is used as a HYPOGLYCEMIC AGENT and supplemental therapy in the treatment of
DIABETES MELLITUS by patients who do not respond to METFORMIN.
https://ansm.sante.fr/actualites/analogues-du-glp-1-et-obesite-nous-prenons-des-mesures-pour-securiser-leur-utilisation-en-france
2025
false
false
false
France
French
patient safety
patient safety
Glucagon-Like Peptide-1 Receptor Agonists
Glucagon-Like Peptide-1 Receptor Agonists
obesity
obesity
france
france
Drug Misuse
Drug Misuse
prescription drug misuse
prescription drug misuse
drug prescriptions
drug prescriptions
critical pathways
critical pathways
semaglutide
semaglutide
pharmacovigilance note
pharmacovigilance note
guideline
guideline
Tirzepatide
Tirzepatide
Liraglutide
Liraglutide
legislation, pharmacy
legislation, pharmacy
---
https://ansm.sante.fr/actualites/diabete-de-type-2-et-tensions-dapprovisionnement-conduite-a-tenir-pour-la-prescription-des-analogues-de-glp1
2023
false
false
false
France
French
incretins
incretins
Glucagon-Like Peptide-1 Receptor
Glucagon-Like Peptide-1 Receptor
guideline
guideline
semaglutide
semaglutide
semaglutide
semaglutide
continuity of patient care
continuity of patient care
hypoglycemic agents
hypoglycemic agents
diabetes mellitus, type 2
diabetes mellitus, type 2
guidelines for drug use
guidelines for drug use
Liraglutide
Liraglutide
break in supply
break in supply
liraglutide
liraglutide
---
https://minerva-ebp.be/FR/Article/2266
2022
Belgium
critical appraisal or critical reading
critical appraisal or critical reading
weight loss
weight loss
Liraglutide
Liraglutide
exercise
exercise
decreased body weight
decreased body weight
healthy volunteers
healthy volunteers
weight loss
weight loss
---
https://www.has-sante.fr/jcms/p_3282773/fr/victoza-liraglutide
2021
false
false
false
France
evaluation of the transparency committee
evaluation of the transparency committee
Liraglutide
Liraglutide
victoza
victoza
---
https://www.has-sante.fr/jcms/c_2894920/en/victoza
2018
false
false
false
France
Liraglutide
Liraglutide
drug therapy, combination
drug therapy, combination
adult
adult
diabetes mellitus, type 2
diabetes mellitus, type 2
injections, subcutaneous
injections, subcutaneous
treatment outcome
treatment outcome
insurance, health, reimbursement
insurance, health, reimbursement
evaluation of the transparency committee
evaluation of the transparency committee
---
Kan liraglutide de kans op type 2-diabetes verminderen bij patiënten met prediabetes?
https://minerva-ebp.be/FR/Article/2164
2018
false
false
false
Belgium
French
Dutch
treatment outcome
treatment outcome
diabetes mellitus, type 2
diabetes mellitus, type 2
prediabetic state
prediabetic state
Liraglutide
Liraglutide
hypoglycemic agents
hypoglycemic agents
incretins
incretins
critical appraisal or critical reading
critical appraisal or critical reading
risk factors
cardiovascular diseases
placebos
obesity
obesity
Glucagon-Like Peptide-1 Receptor
Glucagon-Like Peptide-1 Receptor
blood glucose
blood glucose
weight loss
weight loss
---
https://rmlg.uliege.be/article/2974
2018
false
false
false
false
Belgium
French
journal article
journal article
diabetes mellitus, type 2
diabetes mellitus, type 2
cardiovascular diseases
cardiovascular diseases
hypoglycemic agents
hypoglycemic agents
empagliflozin
empagliflozin
treatment outcome
treatment outcome
empagliflozin
empagliflozin
Sodium-Glucose transporter 2
Sodium-Glucose transporter 2
comparative effectiveness research
comparative effectiveness research
Liraglutide
Liraglutide
liraglutide
liraglutide
Glucagon-Like Peptide-1 Receptor
Glucagon-Like Peptide-1 Receptor
incretins
incretins
case reports
case reports
prognosis
prognosis
cardiovascular diseases
cardiovascular diseases
drug therapy, combination
drug therapy, combination
diabetes mellitus, type 2
diabetes mellitus, type 2
renal insufficiency, chronic
renal insufficiency, chronic
belgium
belgium
insurance, health, reimbursement
insurance, health, reimbursement
Clinical Decision-Making
Clinical Decision-Making
risk factors
risk factors
Sodium-Glucose Transporter 2 Inhibitors
Sodium-Glucose Transporter 2 Inhibitors
benzhydryl compounds
benzhydryl compounds
glucosides
glucosides
---
https://minerva-ebp.be/FR/Analysis/484
2017
false
false
false
Belgium
French
scientific and technical information
scientific and technical information
Liraglutide
Liraglutide
diabetes mellitus, type 2
diabetes mellitus, type 2
cardiovascular diseases
cardiovascular diseases
treatment outcome
treatment outcome
---
https://www.has-sante.fr/jcms/c_2756350/fr/xultophy-insuline-degludec/liraglutide-antidiabetique
https://www.has-sante.fr/jcms/c_2756350/fr/xultophy
2017
false
false
false
false
France
French
evaluation of the transparency committee
evaluation of the transparency committee
drug combinations
drug combinations
insulin degludec and liraglutide
insulin degludec and liraglutide
insulin degludec
insulin degludec
treatment outcome
treatment outcome
insurance, health, reimbursement
insurance, health, reimbursement
hypoglycemic agents
hypoglycemic agents
incretins
incretins
diabetes mellitus, type 2
diabetes mellitus, type 2
adult
adult
drug therapy, combination
drug therapy, combination
injections, subcutaneous
injections, subcutaneous
Liraglutide
Liraglutide
guidelines for drug use
guidelines for drug use
insulin, long-acting
insulin, long-acting
---
https://www.has-sante.fr/jcms/c_2818001/fr/xultophy-insuline-degludec/liraglutide-antidiabetique
https://www.has-sante.fr/jcms/c_2818001/fr/xultophy
2017
false
false
false
false
France
French
evaluation of the transparency committee
evaluation of the transparency committee
drug combinations
drug combinations
insulin degludec and liraglutide
insulin degludec and liraglutide
insulin degludec
insulin degludec
treatment outcome
treatment outcome
insurance, health, reimbursement
insurance, health, reimbursement
hypoglycemic agents
hypoglycemic agents
incretins
incretins
diabetes mellitus, type 2
diabetes mellitus, type 2
adult
adult
injections, subcutaneous
injections, subcutaneous
Liraglutide
Liraglutide
guidelines for drug use
guidelines for drug use
comparative effectiveness research
comparative effectiveness research
insulin, long-acting
insulin, long-acting
---
New antidiabetic medications : at the dawn of a revolution ? New therapeutic options
for type 2 diabetes are challenged for cardiovascular disease prevention
http://www.amub-ulb.be/revue-medicale-bruxelles/article/nouveaux-antidiabetiques-a-laube-dune-revolution-l-1219
2016
false
false
false
Belgium
French
journal article
journal article
hypoglycemic agents
hypoglycemic agents
diabetes mellitus, type 2
diabetes mellitus, type 2
cardiovascular diseases
cardiovascular diseases
empagliflozin
empagliflozin
Liraglutide
Liraglutide
treatment outcome
treatment outcome
myocardial infarction
myocardial infarction
stroke
stroke
cardiovascular diseases
cardiovascular diseases
administration, oral
administration, oral
incretins
incretins
dipeptidyl-peptidase iv inhibitors
dipeptidyl-peptidase iv inhibitors
SGLT2 Inhibitor
SGLT2 Inhibitor
Sodium-Glucose transporter 2
Sodium-Glucose transporter 2
liraglutide
liraglutide
empagliflozin
empagliflozin
Sodium-Glucose Transporter 2 Inhibitors
Sodium-Glucose Transporter 2 Inhibitors
benzhydryl compounds
benzhydryl compounds
glucosides
glucosides
---
https://www.usherbrooke.ca/baladocritique/archives/episode-1-etude-leader/
2016
false
true
false
false
Canada
French
sound
sound
diabetes mellitus, type 2
diabetes mellitus, type 2
Liraglutide
Liraglutide
cardiovascular system
cardiovascular system
episode of
episode of
Diabetes mellitus type 2
Diabetes mellitus type 2
data collection
data collection
diabetes mellitus, type 2
diabetes mellitus, type 2
diabetes non-insulin dependent
diabetes non-insulin dependent
diabetes mellitus, type 1
diabetes mellitus, type 1
effective
effective
Diabetes mellitus type 1
Diabetes mellitus type 1
---
http://www.has-sante.fr/jcms/c_2607357/fr/xultophy
http://www.has-sante.fr/jcms/c_2607357/fr/xultophy-insuline-degludec/liraglutide-antidiabetique
2016
false
false
false
false
France
French
evaluation of the transparency committee
evaluation of the transparency committee
drug combinations
drug combinations
insulin degludec and liraglutide
insulin degludec and liraglutide
insulin degludec
insulin degludec
treatment outcome
treatment outcome
insurance, health, reimbursement
insurance, health, reimbursement
hypoglycemic agents
hypoglycemic agents
incretins
incretins
diabetes mellitus, type 2
diabetes mellitus, type 2
adult
adult
drug therapy, combination
drug therapy, combination
injections, subcutaneous
injections, subcutaneous
Liraglutide
Liraglutide
guidelines for drug use
guidelines for drug use
insulin, long-acting
insulin, long-acting
---
https://www.inesss.qc.ca/thematiques/medicaments/medicaments-evaluation-aux-fins-dinscription/extrait-davis-au-ministre/victoza-3803.html
2016
false
Canada
English
French
Liraglutide
Liraglutide
evaluation of the transparency committee
evaluation of the transparency committee
liraglutide
liraglutide
diabetes mellitus, type 2
diabetes mellitus, type 2
injections, subcutaneous
injections, subcutaneous
treatment outcome
treatment outcome
Cost-Benefit analysis
Cost-Benefit analysis
adult
adult
drug therapy, combination
drug therapy, combination
clinical trials as topic
clinical trials as topic
Product containing glucagon-like peptide 1 receptor agonist (product)
Product containing glucagon-like peptide 1 receptor agonist (product)
Substance with glucagon-like peptide 1 receptor agonist mechanism of action (substance)
Substance with glucagon-like peptide 1 receptor agonist mechanism of action (substance)
comparative study
comparative study
drug evaluation
drug evaluation
---
http://www.riziv.fgov.be/SiteCollectionDocuments/consensus_litterature_resume_20161117.pdf
2016
false
false
false
Belgium
French
GLP-1 Mimetics
GLP-1 Mimetics
diabetes mellitus, type 2
diabetes mellitus, type 2
review of literature
review of literature
consensus
consensus
GLP-1 Mimetics
GLP-1 Mimetics
treatment outcome
treatment outcome
albiglutide
albiglutide
albiglutide
albiglutide
Glucagon-like peptide-1 (GLP-1) analogues
Glucagon-like peptide-1 (GLP-1) analogues
drug therapy, combination
drug therapy, combination
metformin
metformin
hypoglycemic agents
hypoglycemic agents
hypoglycemic agents
hypoglycemic agents
glimepiride
glimepiride
dulaglutide
dulaglutide
dulaglutide
dulaglutide
Liraglutide
Liraglutide
Liraglutide
Liraglutide
Sitagliptin Phosphate
Sitagliptin Phosphate
sulfonylurea compounds
sulfonylurea compounds
comparative effectiveness research
comparative effectiveness research
arterial pressure
arterial pressure
insulin
insulin
thyroid neoplasms
thyroid neoplasms
pancreatitis
pancreatitis
Injection Site Reaction
Injection Site Reaction
cardiovascular diseases
cardiovascular diseases
practice guidelines as topic
practice guidelines as topic
Evidence-Based medicine
Evidence-Based medicine
rGLP-1 protein
rGLP-1 protein
rGLP-1 protein
rGLP-1 protein
glucagon-like peptide 1
glucagon-like peptide 1
glucagon-like peptide 1
glucagon-like peptide 1
glucagon-like peptide 1
glucagon-like peptide 1
immunoglobulin fc fragments
immunoglobulin fc fragments
recombinant fusion proteins
recombinant fusion proteins
glucagon-like peptides
glucagon-like peptides
glucagon-like peptides
glucagon-like peptides
immunoglobulin fc fragments
immunoglobulin fc fragments
recombinant fusion proteins
recombinant fusion proteins
glucagon-like peptides
glucagon-like peptides
peptides
peptides
venoms
venoms
peptides
peptides
venoms
venoms
thiazolidinediones
thiazolidinediones
Pioglitazone
Pioglitazone
Exenatide
Exenatide
Exenatide
Exenatide
---
https://www.ema.europa.eu/medicines/human/EPAR/Saxenda
2015
false
false
false
United Kingdom
French
English
treatment outcome
treatment outcome
syndication feed
syndication feed
summary of product characteristics
summary of product characteristics
package leaflet
package leaflet
drug evaluation
drug evaluation
drug approval
drug approval
europe
europe
obesity
obesity
overweight
overweight
body mass index
body mass index
injections, subcutaneous
injections, subcutaneous
Pre-filled Pen Syringe
Pre-filled Pen Syringe
Injectable Solution Dosage Form
Injectable Solution Dosage Form
product surveillance, postmarketing
product surveillance, postmarketing
adult
adult
aged
aged
drug interactions
drug interactions
pregnancy
pregnancy
breast feeding
breast feeding
drug evaluation, preclinical
drug evaluation, preclinical
obesity
obesity
overweight
overweight
Liraglutide
Liraglutide
Liraglutide
Liraglutide
Glucagon-Like Peptide-1 Receptor
Glucagon-Like Peptide-1 Receptor
---
Réévaluation SMR et ASMR, Renouvellement d'inscription et Modification des conditions
d’inscription
http://www.has-sante.fr/jcms/c_2027892/fr/victoza
2015
false
France
French
Liraglutide
Liraglutide
Liraglutide
Liraglutide
liraglutide
liraglutide
injections, subcutaneous
injections, subcutaneous
diabetes mellitus, type 2
diabetes mellitus, type 2
drug therapy, combination
drug therapy, combination
insurance, health, reimbursement
insurance, health, reimbursement
adult
adult
treatment outcome
treatment outcome
evaluation of the transparency committee
evaluation of the transparency committee
---
https://www.ema.europa.eu/medicines/human/EPAR/XULTOPHY
2014
false
true
false
false
United Kingdom
French
English
drug combinations
drug combinations
insulin degludec and liraglutide
insulin degludec and liraglutide
insulin degludec
insulin degludec
treatment outcome
treatment outcome
hypoglycemic agents
hypoglycemic agents
incretins
incretins
diabetes mellitus, type 2
diabetes mellitus, type 2
adult
adult
drug therapy, combination
drug therapy, combination
injections, subcutaneous
injections, subcutaneous
summary of product characteristics
summary of product characteristics
package leaflet
package leaflet
drug evaluation
drug evaluation
syndication feed
syndication feed
drug approval
drug approval
europe
europe
drug interactions
drug interactions
pregnancy
pregnancy
breast feeding
breast feeding
insulin degludec
insulin degludec
incretins
incretins
hypoglycemic agents
hypoglycemic agents
Liraglutide
Liraglutide
Liraglutide
Liraglutide
insulin, long-acting
insulin, long-acting
insulin, long-acting
insulin, long-acting
---
https://www.ema.europa.eu/medicines/human/EPAR/Victoza
2012
false
United Kingdom
English
French
syndication feed
syndication feed
Liraglutide
Liraglutide
liraglutide
liraglutide
drug approval
drug approval
treatment outcome
treatment outcome
pharmaceutical solutions
pharmaceutical solutions
injections, subcutaneous
injections, subcutaneous
adult
adult
diabetes mellitus, type 2
diabetes mellitus, type 2
drug therapy, combination
drug therapy, combination
hypoglycemic agents
hypoglycemic agents
hypoglycemic agents
hypoglycemic agents
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
drug storage
summary of product characteristics
summary of product characteristics
drug evaluation
drug evaluation
package leaflet
package leaflet
---
http://www.has-sante.fr/upload/docs/application/pdf/2010-01/victoza_-_ct-7136.pdf
http://www.has-sante.fr/jcms/c_945971/victoza-liraglutide-analogue-du-glp-1
2009
false
France
French
Liraglutide
Liraglutide
liraglutide
injections, subcutaneous
diabetes mellitus, type 2
drug therapy, combination
insurance, health, reimbursement
adult
treatment outcome
guidelines for drug use
evaluation of the transparency committee
---